ACM
UTHR icon

Advisors Capital Management’s United Therapeutics UTHR Stock Holding History

Advisors Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Hold
844
– – ﹤0.01% 450
2026
Q1 		$500K Sell
844
-1
-0.1% -$498 0.01% 392
2025
Q4 		$412K Hold
845
– – ﹤0.01% 440
2025
Q3 		$354K Buy
845
+1
+0.1% +$336 ﹤0.01% 450
2025
Q2 		$243K Sell
844
-186
-18% -$55.6K ﹤0.01% 474
2025
Q1 		$318K Sell
1,030
-45
-4% -$15.4K ﹤0.01% 426
2024
Q4 		$379K Buy
1,075
+157
+17% +$57.7K 0.01% 416
2024
Q3 		$329K Buy
+918
New +$310K 0.01% 420

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Advisors Capital Management's UTHR Position: Q2 2026 in Review

Advisors Capital Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 844 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Advisors Capital Management first reported a position in UTHR in Q3 2024 and has held it in 8 quarters since. The position peaked at $500K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Advisors Capital Management held 844 shares of United Therapeutics worth $457K as of Q2 2026.
  • Advisors Capital Management left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Advisors Capital Management's portfolio in Q2 2026, its #450 holding.
  • Advisors Capital Management first reported a position in United Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Advisors Capital Management's United Therapeutics position peaked at $500K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.